Affiliation:
1. Department of Epidemiology and Statistics, School of Public Health, Shanghai Jiao Tong University School of Medicine , Shanghai , China
2. Department of Cardiovascular Medicine, Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China
Abstract
Abstract
BACKGROUND
Alcohol consumption is a proven risk factor of hypertension. In the present analysis, we investigated the use of antihypertensive medications and blood pressure control in male alcohol drinkers and non-drinkers with hypertension (systolic/diastolic blood pressure 160–199/100–119 mm Hg).
METHODS
The study participants were patients enrolled in a 12-week therapeutic study and treated with the irbesartan/hydrochlorothiazide combination 150/12.5 mg once daily, with the possible up-titration to 300/12.5 mg/day and 300/25 mg/day at 4 and 8 weeks of follow-up, respectively, for blood pressure control of <140/90 mm Hg or <130/80 mm Hg in patients with diabetes mellitus. Alcohol consumption was classified as non-drinkers and drinkers.
RESULTS
The 68 alcohol drinkers and 168 non-drinkers had similar systolic/diastolic blood pressure at baseline (160.8 ± 12.1/99.8 ± 8.6 vs. 161.8 ± 11.0/99.2 ± 8.6, P ≥ 0.55) and other characteristics except for current smoking (80.9% vs. 47.6%, P < 0.0001). In patients who completed the 12-week follow-up (n = 215), the use of higher dosages of antihypertensive drugs was similar at 4 weeks of follow-up in drinkers and non-drinkers (10.6% vs. 12.4%, P = 0.70), but increased to a significantly higher proportion in drinkers than non-drinkers at 12 weeks of follow-up (54.7% vs. 36.6%, P = 0.01). The control rate of hypertension tended to be lower in alcohol drinkers, compared with non-drinkers, at 4 weeks of follow-up (45.6% vs. 58.9%, P = 0.06), but became similar at 12 weeks of follow-up (51.5% vs. 54.8%, P = 0.65).
CONCLUSION
Alcohol drinkers compared with non-drinkers required a higher dosage of antihypertensive drug treatment to achieve similar blood pressure control.
CLINICAL TRIAL REGISTRY NUMBER
NCT00670566 at www.clinicaltrials.gov.
Funder
National Natural Science Foundation of China
Ministry of Science and Technology
Ministry of Health
Shanghai Commissions of Science and Technology
Shanghai Municipality for Strengthening the Construction of Public Health System
Shanghai Jiao Tong University School of Medicine
Publisher
Oxford University Press (OUP)
Reference26 articles.
1. Status of hypertension in China: results from the China Hypertension Survey, 2012–2015;Wang;Circulation,2018
2. Patterns and trends of alcohol consumption in rural and urban areas of China: findings from the China Kadoorie Biobank;Im;BMC Public Health,2019
3. Prevalence, awareness, treatment and control rates of hypertension in Chinese adults: trend and associated factors from 1991 to 2015;Yao;Chin Gen Pract,2022
4. Association of lifestyle modification and pharmacological adherence on blood pressure control among patients with hypertension at Kenyatta National Hospital, Kenya: a cross-sectional study;Kimani;BMJ Open,2019
5. Alcohol and hypertension: an analysis using The Health Survey for England, 2014;Grovu;Int J Alcohol Drug Res,2018